The OASIS Consortium: integrating multi-omics technologies to transform chemical safety assessment
Next Generation Risk Assessment (NGRA) aims to improve safety testing of pharmaceuticals, agrochemicals, and industrial chemicals. NGRA employs new approach methodologies, such as novel in vitro assays coupled with exposure modeling, to minimize the use of animal models, which can fail to predict specific biological effects in humans. The strategy of the 'Omics for Assessing Signatures for Integrated Safety (OASIS) Consortium combines multi-omics technologies (including transcriptomics, proteomics, and Cell Painting [high-content imaging]) and multiple cell model systems (ranging from simple cell cultures to complex organotypic models). By integrating these approaches with internal exposure estimates, the consortium aims to improve the translation between in vitro and in vivo test systems, ultimately enhancing the relevance of safety assessment to human biology. OASIS's integrated approach aims to better translate the biological effects across different chemical and biological spaces, starting with the liver as a use case. By using compounds with well-characterized in vivo and in vitro nonclinical safety and toxicology data related to adverse organ-specific effects in rats and humans, OASIS aims to create novel integrated methods that improve safety assessment while reducing animal use. Ideally, these efforts will contribute to regulatory science across sectors and support the adoption of more predictive, efficient, and cost-effective toxicological models.
Authors
- Andreas Bender (ORCID: https://orcid.org/0000-0002-6328-7104)
- Deidre A. Dalmas (ORCID: https://orcid.org/0000-0003-3641-139X)
- Jaime H. Cheah (ORCID: https://orcid.org/0000-0003-4455-4219)
- Srijit Seal (ORCID: https://orcid.org/0000-0003-2790-8679)
- Jessica Ewald (ORCID: https://orcid.org/0000-0002-7555-736X)
- Constance A. Mitchell (ORCID: https://orcid.org/0000-0003-1052-7087)
- Jessica LaRocca
- Anne E. Carpenter (ORCID: https://orcid.org/0000-0003-1555-8261)
- Joshua Harrill (ORCID: https://orcid.org/0000-0003-4317-6391)
- Aaron Fullerton
- Sabah Kadri (ORCID: https://orcid.org/0000-0003-0365-6550)
- Nynke I. Kramer (ORCID: https://orcid.org/0000-0002-3281-1815)
- Shantanu Singh (ORCID: https://orcid.org/0000-0003-3150-3025)
- Nicole Kleinstreuer (ORCID: https://orcid.org/0000-0002-7914-3682)
- David Rouquié (ORCID: https://orcid.org/0000-0002-7796-7418)
- Chrissy Crute
Institutions
- Broad Institute (US)
- National Institutes of Health (US)
- Environmental Protection Agency (US)
- Research Triangle Park Foundation (US)
- Khalifa University of Science and Technology (AE)
- Bechtel (United States) (US)
- University of Cambridge (GB)
- AbbVie (United States) (US)
- Babeș-Bolyai University (RO)
- Corteva (United States) (US)
- Division of Program Coordination Planning and Strategic Initiatives (US)
- Colorado Permanente Medical Group (US)
- Health and Environmental Sciences Institute (US)
- Fondation Sophia Antipolis (FR)
- Institute of Crop Science (JP)
- Oldham Council (GB)
- Wageningen University & Research (NL)
Publication Details
- Journal
- Toxicological Sciences
- Published
- 2025-09-12
- DOI
- https://doi.org/10.1093/toxsci/kfaf128
- Citations
- 5
- Primary Topic
- Animal testing and alternatives
- Type
- article
- Field-Weighted Citation Impact
- 11.77
Funders
- Health and Environmental Sciences Institute
- Massachusetts Life Sciences Center
- Wageningen University and Research